Reading Time: 4 minutes The Pre-brief Clostridioides difficile is a gram-positive anaerobic bacillus that produces spores as well as exotoxins, toxin A and toxin B.…

The results are likely specific to areas without hypervirulent strains of Clostridioides difficile, such as #Australia. #cdiffhttps://t.co/UYlw3BfV3j— Contagion (@Contagion_Live) December 6, 2021

Shared insight on the differences between ACG and IDSA/SHEA treatment guidelines for patients with clostridium difficile infection.

Also known as C. diff for short, Clostridium difficile is an extremely difficult intestinal disease to manage…but not an impossible one. Joining Dr. Neil Nandi to share her insights on how to best mange C. diff in IBD patients is Dr. Jessica Allegretti, the Associate Director of the Crohn's and Colitis Center and the Director of the Fecal Microbiota Transplant Program at the Brigham and Women's Hospital in Boston, Massachusetts.

A panel of experts review treatment goals and assessing response in patients with recurrent clostridium difficile infection.

In this study, increasing CDI trends in annual cohorts of SOT recipients were observed. Posttransplant CDI was associated with mortality, and late-onset CDI was associated with a greater risk of death than early-onset CDI. These findings suggest that preventive strategies should not be limited to th …

Experts review the impact that medications, antibiotic or otherwise, may have on the development of Clostridioides difficile infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discusses the current treatment strategies for C. diff infection and recurrent C. diff infection, as well as the efficacy and safety of these treatments.

A broad view on the impact of recurrent clostridium difficile infection on patients and the healthcare system at large.

Payer participants break down how coverage criteria are determined for treatments for clostridium difficile infection.

Medicare beneficiaries have limited access to recommended treatments for Clostridioides difficile infection, researchers reported in Clinical Infectious Diseases. In June, the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America published updated guidelines for managing C. difficile infection (CDI), which included a recommendation to use fidaxomicin over oral

In this Healio Gastroenterology video exclusive, Jessica R. Allegretti, MD, MPH, director of the fecal microbiota center at Brigham and Women’s Hospital, discussed treatment options for recurrence for Clostridioides difficile infection. Allegretti moderated the symposium at Advances in Inflammatory Bowel Diseases 2021.

Pharmacists play an important role in educating patients and other health care practitioners on the signs and symptoms of C. difficile infection.

Panelists take a step back to consider the broader challenges in managing patients with clostridium difficile infection.

Experts consider optimal approaches to administering therapy for CDI and share insight on available treatment guidelines.

Centering their discussion around a patient case of CDI, experts discuss optimal therapy selection given available agents and guidelines.

Using a non-aqueous vehicle and sweeteners to improve palatability, pharmacists and technicians can ensure that young patients remain medication adherent.

At least 3 companies have presented later phase data on live microbiota therapies for treating recurrent C difficile infections in 2021.

Debra Goff, PharmD, FIDSA, FCCP, infectious diseases specialist at the Ohio State University Wexner Medical Center, discusses Clostridioides difficile awareness and potential future treatments.

Recent studies have indicated more community spread of C difficile infections.

The club caught up with midfielder Mia Ross following yesterday’s victory against London City Lionesses in the FA Women’s Championship. The 18-year-old scored her first goal for the Addicks on Sunday afternoon, heading past Shae Yanez in the tenth minute.  “We wanted to bounce back from the past results that we’ve had,” Ross explained. “I […]

Several companies are testing live microbiota therapies for C difficile infections.

Recurrent Clostridioides difficile infection is common, yet few clinicians follow up with these patients. The researchers also found that nearly 50% of patients with rCDI had to be rehospitalized...

pAccording to a recent meta-analysis, emSaccharomyces boulardii/em does not significantly reduce the risk for primary or recurrent emClostridioides difficile/em infection in inpatients and outpatients receiving antibiotic therapy./pdiv /div

Economic evaluations for CDI assess narrowly defined decision problems which may have implications for optimal healthcare resource allocation.

The Gram-positive bacterium Clostridioides difficile is a primary cause of hospital-acquired diarrhea, threatening both immunocompromised and healthy individuals. An important aspect of defining mechanisms that drive C. difficile persistence and virulence relies on developing a more co …

NCT02218372.